CRISPR THERAPEUTICS AG
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2019 | $127.3M | $1.07B | $943.8M |
| FY2020 | $163.7M | $1.83B | $1.17B |
| FY2021 | $352.4M | $2.75B | $923.0M |
| FY2022 | $367.6M | $2.24B | $211.9M |
| FY2023 | $346.8M | $2.23B | $389.5M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2019 | $127.3M | $1.07B | $943.8M |
| FY2020 | $163.7M | $1.83B | $1.17B |
| FY2021 | $352.4M | $2.75B | $923.0M |
| FY2022 | $367.6M | $2.24B | $211.9M |
| FY2023 | $346.8M | $2.23B | $389.5M |